کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5524053 1546236 2017 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation
ترجمه فارسی عنوان
ترومبوپوئیتین انسانی انسانی، ترویج تزریق انسولین وریدی و پیش آگهی بیماران مبتلا به سندرم های میلوادای پلاسمی و آنمی آپالیستی پس از پیوند آلوژنیک سلول های بنیادی هماتوپوئیدی را بهبود می بخشد
کلمات کلیدی
عملکرد پیوند پلاکت پیوند سلول بنیادی، ترومبوپوتین بازسازی کننده انسانی، پیش بینی،
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی


- Recombinant human thrombopoietin promotes platelet engraftment in patients after allogeneic hematopoietic stem cell transplantation
- The 3-year overall survival rate of patients with poor platelet graft function was significantly less than that of patients with good platelet graft function
- In patients with myelodysplastic syndromes or aplastic anemia, recombinant human thrombopoietin was associated with a significant survival advantage

Poor platelet graft function (PPGF) is a significant complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no optimal treatment has been recommended. This study investigated aspects of platelet recovery after allo-HSCT, including prognostic value and the effect of recombinant human thrombopoietin (rhTPO). We retrospectively analyzed 275 patients who received allo-HSCT in our center. Of them, 135 (49.1%) patients had good platelet graft function (GPGF) and 140 (50.9%) had PPGF. The latter included 59 (21.5%) patients with primary PPGF and 81 (29.4%) with secondary PPGF. Multivariate analysis showed that male gender (P = .024), lower CD34+ cell count (P = .04), and no use of rhTPO (P <.001) were associated with PPGF. The 3-year overall survival rate of patients with PPGF (58%) was significantly less than that of patients with GPGF (82%; P <.001). We further analyzed the effect of rhTPO on prognosis of patients after allo-HSCT. Although no advantage was apparent when analyzing the entire cohort, for patients with myelodysplastic syndromes and aplastic anemia, rhTPO was associated with a significant survival advantage (P = .014).

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biology of Blood and Marrow Transplantation - Volume 23, Issue 10, October 2017, Pages 1678-1684
نویسندگان
, , , , , , , , , , , ,